基于对比剂类型的MRI对局部区域治疗后肝细胞癌残留或复发的诊断效能:系统评价与Meta分析
该系统评价与Meta分析纳入15项研究共803例患者和1018个病灶,比较细胞外对比剂MRI(ECA-MRI)与肝细胞特异性对比剂MRI(EOB-MRI)对局部区域治疗后肝细胞癌残留或复发的诊断效能。结果显示ECA-MRI与EOB-MRI的汇总敏感度(87% vs. 79%)和特异度(92% vs. 96%)无显著差异(P=0.41),HSROC曲线下面积分别为0.95和0.92,亚组分析各变量下均无显著差异(均P>0.05)。
要点
- ECA-MRI与EOB-MRI检测局部区域治疗后HCC残留或复发的汇总敏感度87% vs. 79%、特异度92% vs. 96%,无显著差异(P=0.41)。
- HSROC曲线下面积ECA-MRI为0.95、EOB-MRI为0.92,诊断效能总体相当。
- 亚组分析(研究设计、LRT类型、病因、基线病灶大小、检查时间、场强)均未见两种对比剂诊断效能显著差异(均P>0.05)。
核心结论
- ECA-MRI在评估局部区域治疗后HCC残留或复发方面总体诊断效能与EOB-MRI相当。
研究设计与样本
- 系统评价与Meta分析,纳入15项原始研究,共803例患者和1018个病灶;检索PubMed、EMBASE、Cochrane Library和Web of Science数据库。
诊断标准与关键数值
- ECA-MRI检测局部区域治疗后HCC残留或复发的汇总敏感度为87%,EOB-MRI为79%。
- ECA-MRI检测局部区域治疗后HCC残留或复发的汇总特异度为92%,EOB-MRI为96%。
- ECA-MRI与EOB-MRI的汇总敏感度和特异度差异无统计学意义(P=0.41)。
- HSROC曲线下面积ECA-MRI为0.95,EOB-MRI为0.92。
- 亚组分析按研究设计、LRT类型、肝病最常见病因、基线病灶大小、治疗后检查时间和MRI场强分组,两种对比剂诊断效能均无显著差异(均P>0.05)。
临床应用与阅片要点
- 作者结论认为,ECA-MRI在评估局部区域治疗后HCC残留或复发方面总体诊断效能与EOB-MRI相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The ideal contrast agent for imaging patients with hepatocellular carcinoma (HCC) following locoregional therapies (LRT) remains uncertain. We conducted a meta-analysis to assess the diagnostic performance of magnetic resonance imaging with extracellular contrast agent (ECA-MRI) and hepatobiliary agent (EOB-MRI) in detecting residual or recurrence HCC following LRT.
METHODS: Original studies comparing the diagnostic performance of ECA-MRI and EOB-MRI were systematically identified through comprehensive searches in PubMed, EMBASE, Cochrane Library and Web of Science databases. The pooled sensitivity and specificity of ECA-MRI and EOB-MRI were calculated using a bivariate-random-effects model. Subgroup-analyses were conducted to compare the diagnostic performance of ECA-MRI and EOB-MRI according to different variables. Meta-regression analysis was employed to explore potential sources of study heterogeneity.
RESULTS: A total of 15 eligible studies encompassing 803 patients and 1018 lesions were included. Comparative analysis revealed no significant difference between ECA-MRI and EOB-MRI in the overall pooled sensitivity (87% vs. 79%) and specificity (92% vs. 96%) for the detection of residual or recurrent HCC after LRT (P = 0.41), with comparable areas under the HSROC of 0.95 and 0.92. Subgroup analyses indicated no significant diagnostic performance differences between ECA-MRI and EOB-MRI according to study design, type of LRT, most common etiology of liver disease, baseline lesion size, time of post-treated examination and MRI field strength (All P > 0.05).
CONCLUSION: ECA-MRI exhibited overall comparable diagnostic performance to EOB-MRI in assessing residual or recurrent HCC after LRT.
引用
- Zhou S, Wang S, Xiang J, et al. Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis. Abdom Radiol (NY). 2024. PMID: 38200213. doi:10.1007/s00261-023-04143-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。